Academic Journal
Προβολή σε EDS
Συνδεδεμένο Πλήρες Κείμενο

Long-term impact of Elexacaftor/Tezacaftor/ivacaftor on pulmonary, nutritional and metabolic outcomes in homozygous F508del cystic fibrosis patients: A real-world cohort study.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: Long-term impact of Elexacaftor/Tezacaftor/ivacaftor on pulmonary, nutritional and metabolic outcomes in homozygous F508del cystic fibrosis patients: A real-world cohort study.
Συγγραφείς: Perrotta N; Department of Physiology and Pharmacology 'V. Erspamer', Sapienza University, Rome, Italy.; Policlinico Umberto I Hospital, Sapienza University, Rome, Italy., Fiorito LA; Department of Physiology and Pharmacology 'V. Erspamer', Sapienza University, Rome, Italy.; Policlinico Umberto I Hospital, Sapienza University, Rome, Italy., Vescovo R; Department of Chemistry and Technology of Drugs, Sapienza University, Rome, Italy., Virgilio A; Department of Chemistry and Technology of Drugs, Sapienza University, Rome, Italy., Amato G; Department of Chemistry and Technology of Drugs, Sapienza University, Rome, Italy., Cimino G; Regional Cystic Fibrosis Center, Policlinico Umberto I Hospital, Sapienza University, Rome, Italy.
Πηγή: British journal of clinical pharmacology [Br J Clin Pharmacol] 2026 Jun; Vol. 92 (6), pp. 1822-1832. Date of Electronic Publication: 2026 Jan 23.
Τύπος έκδοσης: Journal Article
Γλώσσα: English
Στοιχεία περιοδικού: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 7503323 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2125 (Electronic) Linking ISSN: 03065251 NLM ISO Abbreviation: Br J Clin Pharmacol Subsets: MEDLINE
Imprint Name(s): Publication: Oxford : Wiley-Blackwell
Original Publication: London, Macmillan Journals Ltd.
Ιατρικοί όροι (MeSH): Cystic Fibrosis*/drug therapy , Cystic Fibrosis*/physiopathology , Cystic Fibrosis*/genetics , Cystic Fibrosis*/metabolism , Quinolones*/therapeutic use , Quinolones*/administration & dosage , Indoles*/therapeutic use , Indoles*/administration & dosage , Pyrrolidines*/therapeutic use , Pyrrolidines*/administration & dosage , Aminophenols*/therapeutic use , Aminophenols*/administration & dosage , Aminophenols*/pharmacology , Pyridines*/therapeutic use , Pyridines*/administration & dosage , Pyrazoles*/therapeutic use , Pyrazoles*/administration & dosage , Benzodioxoles*/therapeutic use, Nutritional Status/drug effects ; Cystic Fibrosis Transmembrane Conductance Regulator/genetics ; Lung/drug effects ; Lung/physiopathology ; Chloride Channel Agonists/therapeutic use ; Chloride Channel Agonists/administration & dosage ; Humans ; Female ; Adult ; Male ; Retrospective Studies ; Adolescent ; Young Adult ; Child ; Treatment Outcome
Περίληψη: Aim: Elexacaftor/tezacaftor/ivacaftor (ETI) has markedly improved cystic fibrosis (CF) outcomes. However, its long-term impact on nutrition, metabolism and liver health remains underexplored. We assessed 30-month changes in pulmonary, nutritional, metabolic and inflammatory markers in people with CF (PwCF) homozygous for F508del.
Methods: We retrospectively analysed 112 PwCF (median age-31 years) treated with ETI from July 2021 to December 2024. Clinical, spirometric and biochemical data were collected at baseline and at 6, 12, 24 and 30 months.
Results: ETI produced sustained lung function gains (percent predicted FEV₁ + 15 points at 24 months, p < 0.001), BMI increase (+1.7 kg/m2 in year-one, p < 0.001) and marked C-reactive protein reduction (-80% at 6 months), with an 85% decrease in pulmonary exacerbations. Nutritional recovery shifted BMI distribution: underweight prevalence declined from 12.5% to 1.8%, while overweight rose from 15.2% to 27.7%. Adolescents improved in weight-for-age Z-scores (+0.42, p = 0.01). Total and LDL cholesterol increased but remained within reference ranges; HDL, triglycerides and glycaemic control stayed stable, with no new cystic fibrosis-related diabetes (CFRD). Vitamin D improved; vitamin B12 fluctuated with supplementation. Mild, transient transaminase elevations occurred in 4.5% of PwCF, with no fibrosis progression (APRI/FIB-4 below risk thresholds).
Conclusion: ETI provides durable multisystem benefits, preserving lung function and improving nutritional and metabolic profiles. However, the shift towards overweight/obesity and biochemical signs of hepatic stress suggests evolving cardiometabolic risks. These findings support early ETI initiation and reinforce the need for ongoing monitoring of nutrition, lipid profile and liver function, together with updated CF care strategies to mitigate long-term cardiometabolic complications.
(© 2026 The Author(s). British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.)
References: Snowball JE, Flight WG, Heath L, Koutoukidis DA. A paradigm shift in cystic fibrosis nutritional care: clinicians' views on the management of patients with overweight and obesity. J Cyst Fibros. 2023;22(5):836‐842. doi:10.1016/j.jcf.2023.03.011.
Bell SC, Mall MA, Gutierrez H, et al. The future of cystic fibrosis care: a global perspective. Lancet Respir Med. 2019;7(12):e40. doi:10.1016/S2213‐2600(19)30408‐4.
Bardin E, Pastor A, Semeraro M, et al. Modulators of CFTR. Updates on clinical development and future directions. Eur J Med Chem. 2021;213:113195. doi:10.1016/j.ejmech.2021.113195.
Frantzen T, Barsky S, LaVecchia G, Marowitz M, Wang J. Evolving nutritional needs in cystic fibrosis. Life. 2023;13(7):1431. doi:10.3390/life13071431.
Despotes KA, Ceppe AS, Donaldson SH. Alterations in lipids after initiation of highly effective modulators in people with cystic fibrosis. J Cyst Fibros. 2023;22(6):1024‐1026. doi:10.1016/j.jcf.2023.10.002.
Middleton PG, Mall MA, Dřevínek P, et al. Elexacaftor‐Tezacaftor‐ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med. 2019;381(19):1809‐1819. doi:10.1056/NEJMoa1908639.
Moran A, Brunzell C, Cohen RC, et al. CFRD guidelines committee. Clinical care guidelines for cystic fibrosis‐related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the pediatric Endocrine Society. Diabetes Care. 2010;33(12):2697‐2708. doi:10.2337/dc10‐1768.
Wilschanski M, Munck A, Carrion E, et al. ESPEN‐ESPGHAN‐ECFS guideline on nutrition care for cystic fibrosis. Clin Nutr. 2024;43(2):413‐445. doi:10.1016/j.clnu.2023.12.017.
Quanjer PH, Stanojevic S, Cole TJ, et al. Multi‐ethnic reference values for spirometry for the 3‐95‐yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40(6):1324‐1343. doi:10.1183/09031936.00080312.
Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518‐526. doi:10.1053/jhep.2003.50346.
Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317‐1325. doi:10.1002/hep.21178.
Sellers Z, Assis D, Paranjape S, et al. Cystic fibrosis screening, evaluation, and management of hepatobiliary disease consensus recommendations. Hepatology. 2024;79(5):1220‐1238. doi:10.1097/HEP.0000000000000646.
Heijerman HGM, McKone EF, Downey DG, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double‐blind, randomised, phase 3 trial. Lancet. 2019;394(10212):1940‐1948. doi:10.1016/S0140‐6736(19)32597‐8.
Vega‐Hernandez G, MacGregor G, Wilfin A, et al. LONGITUDE: an observational study of the long‐term effectiveness of elexacaftor/tezacaftor/ivacaftor in people aged ≥12 years with cystic fibrosis using data from the United Kingdom cystic fibrosis registry ‐ 2‐year analysis. J Cyst Fibros. 24(4):716‐723. doi:10.1016/j.jcf.2025.04.012.
Perrotta N, Fiorito LA, Gentile R, et al. Real‐world evaluation of outcomes and safety of Elexacaftor/Tezacaftor/ivacaftor in pediatric patients with cystic fibrosis: a retrospective study. Clin Transl Sci. 2025;18(10):e70373. doi:10.1111/cts.70373.
Keens T, Hoffman V, Topuria I, et al. VX19‐CFD‐003 study group. Real‐world effectiveness of elexacaftor/tezacaftor/ivacaftor on the burden of illness in adolescents and adults with cystic fibrosis. Heliyon. 2024;10(7):e28508. doi:10.1016/j.heliyon.2024.e28508.
Perrotta N, Fiorito LA, Casini G, et al. Improved clinical outcomes with Elexacaftor/Tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease: real‐world evidence from an Italian single‐center study. Pharmacol Res Perspect. 2025;13(2):e70083. doi:10.1002/prp2.70083.
López Cárdenes CM, Merino Sánchez‐Cañete A, Vicente Santamaría S, et al. Effects on growth, weight and body composition after CFTR modulators in children with cystic fibrosis. Pediatr Pulmonol. 2024;59(12):3632‐3640. doi:10.1002/ppul.27272.
Sandersa DB, Zhangb Z, Farrellc P, Lai HCJ. Early life growth patterns persist for 12 years and impact pulmonary outcomes in cystic fibrosis. J Cyst Fibros. 2018;17(4):528‐535. doi:10.1016/j.jcf.2018.01.006.
Westhölter D, Haubold J, Welsner M, et al. Elexacaftor/tezacaftor/ivacaftor influences body composition in adults with cystic fibrosis: a fully automated CT‐based analysis. Sci Rep. 2024;14(1):9465. doi:10.1038/s41598‐024‐59622‐2.
Castaldo A, Cimbalo C, Fevola C, et al. The treatment with Elexacaftor/Tezacaftor/ivacaftor significantly increases serum bilirubin and decreases blood platelets in children and adolescents with cystic fibrosis homozygous or double heterozygous for the F508del CFTR variant. J Cyst Fibros. 24(6):1149‐1155.
Pepe A, Fevola C, Dolce D, et al. Elexacaftor/tezacaftor/ivacaftor and inflammation in children and adolescents with cystic fibrosis: a retrospective dual‐center cohort study. Ther Adv Respir Dis. 2025;19. doi:10.1177/17534666251314706.
Bailey J, Krick S, Fontaine KR. The changing landscape of nutrition in cystic fibrosis: the emergence of overweight and obesity. Nutrients. 2022;14(6):1216. doi:10.3390/nu14061216.
Castaldo A, Iacotucci P, Bagnasco S, et al. Liver biochemical indexes and cholesterol metabolism in cystic fibrosis patients with F508del/CFTR variant genotype after elexacaftor/tezacaftor/ivacaftor treatment. Sci Rep. 2024;14(1):17422. doi:10.1038/s41598‐024‐68511‐7.
Vavrina K, Griffin TB, Jones AM, Schindler T, Bui TN, Sankararaman S. Evolving nutrition therapy in cystic fibrosis: adapting to the CFTR modulator era. Nutr Clin Pract. 2025;40(4):816‐828. doi:10.1002/ncp.11332.
Ratti GA, Smith H, Mirfakhraee S, et al. Development of metabolic syndrome in people with cystic fibrosis one year after exposure to elexacaftor‐tezacaftor‐ivacaftor. J Cyst Fibros. 2025;24(1):47‐52. doi:10.1016/j.jcf.2024.09.022.
Castaldo A, Gelzo M, Iacotucci P, et al. One year of treatment with elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis homozygous for the F508del mutation causes a significant increase in liver biochemical indexes. Front. Mol. Biosci., 08 January 2024. Sec Cell Biochem. 2023;10.
Clayton LJ, Shepherd AI, Corbett J, et al. Cardiovascular function in people with cystic fibrosis on Elexacaftor/Tezacaftor/ivacaftor: a cross‐sectional, observational, single‐Centre study. J Cyst Fibros. 2025;S1569‐1993(25):00052‐00059. doi:10.1016/j.jcf.2025.02.001.
Betapudi B, Aleem A, Kothadia JP. Cystic Fibrosis and Liver Disease. 2023 Jan 9. In: StatPearls. StatPearls Publishing; 2025. PMID: 32310546.
Liang X, Hou X, Bouhamdan M, et al. Sotagliflozin attenuates liver‐associated disorders in cystic fibrosis rabbits. JCI Insight. 2024;9(6):e165826. doi:10.1172/jci.insight.165826.
Ticona JH, Lapinel N, Wang J. Future comorbidities in an aging cystic fibrosis population. Life (Basel). 2023;13(6):1305. doi:10.3390/life13061305.
Blankenship S, Landis AR, Harrison Williams E, et al. What the future holds: cystic fibrosis and aging. Front Med (Lausanne). 2024;10:1340388. doi:10.3389/fmed.2023.1340388.
Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cystic fibrosis‐related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care. 2009;32(9):1626‐1631. doi:10.2337/dc09‐0586.
Merjaneh L, Hasan S, Kasim N, Ode KL. The role of modulators in cystic fibrosis related diabetes. J Clin Transl Endocrinol. 2021;27:100286. doi:10.1016/j.jcte.2021.100286.
Lurquin F, Gohy S. Hermans MP et al combined CFTR modulator therapies are linked with anabolic benefits and insulin‐sparing in cystic fibrosis‐related diabetes. J Clin Transl Endocrinol. 2023;33:100320. doi:10.1016/j.jcte.2023.100320.
Lurquin F, Buysschaert M, Preumont V. Advances in cystic fibrosis‐related diabetes: current status and future directions. Diabetes Metab Syndr. 2023;17(11):102899. doi:10.1016/j.dsx.2023.102899.
Sankararaman S, Hendrix SJ, Schindler T. Update on the management of vitamins and minerals in cystic fibrosis. Nutr Clin Pract. 2022;37(5):1074‐1087. doi:10.1002/ncp.10899.
Hergenroeder GE, Faino A, Bridges G, et al. The impact of elexacaftor/tezacaftor/ivacaftor on fat‐soluble vitamin levels in people with cystic fibrosis. J Cyst Fibros. 2023;22(6):1048‐1053. doi:10.1016/j.jcf.2023.08.002.
Crehuá‐Gaudiza E, Vicente Santamaría S, Álvarez Beltrán M, et al. Effect of cystic fibrosis modulator therapies on serum levels of fat‐soluble vitamins. JPGN Rep. 2025;6(2):146‐152. doi:10.1002/jpr3.70007.
Jarosz‐Griffiths HH, Caley LR, Lara‐Reyna S, et al. Heightened mitochondrial respiration in CF cells is normalised by triple CFTR modulator therapy through mechanisms involving calcium. Heliyon. 2024;10(20):e39244. doi:10.1016/j.heliyon.2024.e39244.
Zhang S, Shrestha CL, Robledo‐Avila F, et al. Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor. Eur Respir J. 2023;61(4):2102861. doi:10.1183/13993003.02861‐2021.
Tewkesbury DH, Athwal V, Bright‐Thomas RJ, Jones AM, Barry PJ. Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on liver tests at a large single adult cystic fibrosis Centre. J Cyst Fibros. 2023;22(2):256‐262. doi:10.1016/j.jcf.2023.01.007.
Contributed Indexing: Keywords: Elexacaftor/Tezacaftor/ivacaftor; cystic fibrosis; inflammation; liver function; metabolic health; nutritional status
Substance Nomenclature: 0 (Quinolones)
0 (Indoles)
0 (Pyrrolidines)
0 (Aminophenols)
RRN67GMB0V (elexacaftor)
8RW88Y506K (tezacaftor)
0 (Pyridines)
126880-72-6 (Cystic Fibrosis Transmembrane Conductance Regulator)
0 (Pyrazoles)
0 (Benzodioxoles)
0 (Chloride Channel Agonists)
Entry Date(s): Date Created: 20260124 Date Completed: 20260630 Latest Revision: 20260630
Update Code: 20260701
PubMed Central ID: PMC13206182
DOI: 10.1002/bcp.70460
PMID: 41578635
Βάση Δεδομένων: MEDLINE
FullText Links:
  – Type: other
    Url: https://resolver.ebsco.com:443/public/rma-ftfapi/ejs/direct?AccessToken=4307AE104130B5755CEC&Show=Object
Text:
  Availability: 0
Header DbId: cmedm
DbLabel: MEDLINE
An: 41578635
AccessLevel: 3
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Long-term impact of Elexacaftor/Tezacaftor/ivacaftor on pulmonary, nutritional and metabolic outcomes in homozygous F508del cystic fibrosis patients: A real-world cohort study.
– Name: Author
  Label: Authors
  Group: Au
  Data: &lt;searchLink fieldCode=&quot;AU&quot; term=&quot;%22Perrotta+N%22&quot;&gt;Perrotta N&lt;/searchLink&gt;; Department of Physiology and Pharmacology &#39;V. Erspamer&#39;, Sapienza University, Rome, Italy.; Policlinico Umberto I Hospital, Sapienza University, Rome, Italy.&lt;br /&gt;&lt;searchLink fieldCode=&quot;AU&quot; term=&quot;%22Fiorito+LA%22&quot;&gt;Fiorito LA&lt;/searchLink&gt;; Department of Physiology and Pharmacology &#39;V. Erspamer&#39;, Sapienza University, Rome, Italy.; Policlinico Umberto I Hospital, Sapienza University, Rome, Italy.&lt;br /&gt;&lt;searchLink fieldCode=&quot;AU&quot; term=&quot;%22Vescovo+R%22&quot;&gt;Vescovo R&lt;/searchLink&gt;; Department of Chemistry and Technology of Drugs, Sapienza University, Rome, Italy.&lt;br /&gt;&lt;searchLink fieldCode=&quot;AU&quot; term=&quot;%22Virgilio+A%22&quot;&gt;Virgilio A&lt;/searchLink&gt;; Department of Chemistry and Technology of Drugs, Sapienza University, Rome, Italy.&lt;br /&gt;&lt;searchLink fieldCode=&quot;AU&quot; term=&quot;%22Amato+G%22&quot;&gt;Amato G&lt;/searchLink&gt;; Department of Chemistry and Technology of Drugs, Sapienza University, Rome, Italy.&lt;br /&gt;&lt;searchLink fieldCode=&quot;AU&quot; term=&quot;%22Cimino+G%22&quot;&gt;Cimino G&lt;/searchLink&gt;; Regional Cystic Fibrosis Center, Policlinico Umberto I Hospital, Sapienza University, Rome, Italy.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: &lt;searchLink fieldCode=&quot;JN&quot; term=&quot;%227503323%22&quot;&gt;British journal of clinical pharmacology&lt;/searchLink&gt; [Br J Clin Pharmacol] 2026 Jun; Vol. 92 (6), pp. 1822-1832. &lt;i&gt;Date of Electronic Publication: &lt;/i&gt;2026 Jan 23.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: Language
  Label: Language
  Group: Lang
  Data: English
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: &lt;i&gt;Publisher: &lt;/i&gt;&lt;searchLink fieldCode=&quot;PB&quot; term=&quot;%22Wiley-Blackwell%22&quot;&gt;Wiley-Blackwell &lt;/searchLink&gt;&lt;i&gt;Country of Publication: &lt;/i&gt;England &lt;i&gt;NLM ID: &lt;/i&gt;7503323 &lt;i&gt;Publication Model: &lt;/i&gt;Print-Electronic &lt;i&gt;Cited Medium: &lt;/i&gt;Internet &lt;i&gt;ISSN: &lt;/i&gt;1365-2125 (Electronic) &lt;i&gt;Linking ISSN: &lt;/i&gt;&lt;searchLink fieldCode=&quot;IS&quot; term=&quot;%2203065251%22&quot;&gt;03065251 &lt;/searchLink&gt;&lt;i&gt;NLM ISO Abbreviation: &lt;/i&gt;Br J Clin Pharmacol &lt;i&gt;Subsets: &lt;/i&gt;MEDLINE
– Name: PublisherInfo
  Label: Imprint Name(s)
  Group: PubInfo
  Data: &lt;i&gt;Publication&lt;/i&gt;: Oxford : Wiley-Blackwell&lt;br /&gt;&lt;i&gt;Original Publication&lt;/i&gt;: London, Macmillan Journals Ltd.
– Name: SubjectMESH
  Label: MeSH Terms
  Group: Su
  Data: &lt;searchLink fieldCode=&quot;MM&quot; term=&quot;%22Cystic+Fibrosis%22&quot;&gt;Cystic Fibrosis*&lt;/searchLink&gt;/&lt;searchLink fieldCode=&quot;MM&quot; term=&quot;%22Cystic+Fibrosis+drug+therapy%22&quot;&gt;drug therapy&lt;/searchLink&gt; &lt;br /&gt;&lt;searchLink fieldCode=&quot;MM&quot; term=&quot;%22Cystic+Fibrosis%22&quot;&gt;Cystic Fibrosis*&lt;/searchLink&gt;/&lt;searchLink fieldCode=&quot;MM&quot; term=&quot;%22Cystic+Fibrosis+physiopathology%22&quot;&gt;physiopathology&lt;/searchLink&gt; &lt;br /&gt;&lt;searchLink fieldCode=&quot;MM&quot; term=&quot;%22Cystic+Fibrosis%22&quot;&gt;Cystic Fibrosis*&lt;/searchLink&gt;/&lt;searchLink fieldCode=&quot;MM&quot; term=&quot;%22Cystic+Fibrosis+genetics%22&quot;&gt;genetics&lt;/searchLink&gt; &lt;br /&gt;&lt;searchLink fieldCode=&quot;MM&quot; term=&quot;%22Cystic+Fibrosis%22&quot;&gt;Cystic Fibrosis*&lt;/searchLink&gt;/&lt;searchLink fieldCode=&quot;MM&quot; term=&quot;%22Cystic+Fibrosis+metabolism%22&quot;&gt;metabolism&lt;/searchLink&gt; &lt;br /&gt;&lt;searchLink fieldCode=&quot;MM&quot; term=&quot;%22Quinolones%22&quot;&gt;Quinolones*&lt;/searchLink&gt;/&lt;searchLink fieldCode=&quot;MM&quot; term=&quot;%22Quinolones+therapeutic+use%22&quot;&gt;therapeutic use&lt;/searchLink&gt; &lt;br /&gt;&lt;searchLink fieldCode=&quot;MM&quot; term=&quot;%22Quinolones%22&quot;&gt;Quinolones*&lt;/searchLink&gt;/&lt;searchLink fieldCode=&quot;MM&quot; term=&quot;%22Quinolones+administration+%26+dosage%22&quot;&gt;administration &amp; dosage&lt;/searchLink&gt; &lt;br /&gt;&lt;searchLink fieldCode=&quot;MM&quot; term=&quot;%22Indoles%22&quot;&gt;Indoles*&lt;/searchLink&gt;/&lt;searchLink fieldCode=&quot;MM&quot; term=&quot;%22Indoles+therapeutic+use%22&quot;&gt;therapeutic use&lt;/searchLink&gt; &lt;br /&gt;&lt;searchLink fieldCode=&quot;MM&quot; term=&quot;%22Indoles%22&quot;&gt;Indoles*&lt;/searchLink&gt;/&lt;searchLink fieldCode=&quot;MM&quot; term=&quot;%22Indoles+administration+%26+dosage%22&quot;&gt;administration &amp; dosage&lt;/searchLink&gt; &lt;br /&gt;&lt;searchLink fieldCode=&quot;MM&quot; term=&quot;%22Pyrrolidines%22&quot;&gt;Pyrrolidines*&lt;/searchLink&gt;/&lt;searchLink fieldCode=&quot;MM&quot; term=&quot;%22Pyrrolidines+therapeutic+use%22&quot;&gt;therapeutic use&lt;/searchLink&gt; &lt;br /&gt;&lt;searchLink fieldCode=&quot;MM&quot; term=&quot;%22Pyrrolidines%22&quot;&gt;Pyrrolidines*&lt;/searchLink&gt;/&lt;searchLink fieldCode=&quot;MM&quot; term=&quot;%22Pyrrolidines+administration+%26+dosage%22&quot;&gt;administration &amp; dosage&lt;/searchLink&gt; &lt;br /&gt;&lt;searchLink fieldCode=&quot;MM&quot; term=&quot;%22Aminophenols%22&quot;&gt;Aminophenols*&lt;/searchLink&gt;/&lt;searchLink fieldCode=&quot;MM&quot; term=&quot;%22Aminophenols+therapeutic+use%22&quot;&gt;therapeutic use&lt;/searchLink&gt; &lt;br /&gt;&lt;searchLink fieldCode=&quot;MM&quot; term=&quot;%22Aminophenols%22&quot;&gt;Aminophenols*&lt;/searchLink&gt;/&lt;searchLink fieldCode=&quot;MM&quot; term=&quot;%22Aminophenols+administration+%26+dosage%22&quot;&gt;administration &amp; dosage&lt;/searchLink&gt; &lt;br /&gt;&lt;searchLink fieldCode=&quot;MM&quot; term=&quot;%22Aminophenols%22&quot;&gt;Aminophenols*&lt;/searchLink&gt;/&lt;searchLink fieldCode=&quot;MM&quot; term=&quot;%22Aminophenols+pharmacology%22&quot;&gt;pharmacology&lt;/searchLink&gt; &lt;br /&gt;&lt;searchLink fieldCode=&quot;MM&quot; term=&quot;%22Pyridines%22&quot;&gt;Pyridines*&lt;/searchLink&gt;/&lt;searchLink fieldCode=&quot;MM&quot; term=&quot;%22Pyridines+therapeutic+use%22&quot;&gt;therapeutic use&lt;/searchLink&gt; &lt;br /&gt;&lt;searchLink fieldCode=&quot;MM&quot; term=&quot;%22Pyridines%22&quot;&gt;Pyridines*&lt;/searchLink&gt;/&lt;searchLink fieldCode=&quot;MM&quot; term=&quot;%22Pyridines+administration+%26+dosage%22&quot;&gt;administration &amp; dosage&lt;/searchLink&gt; &lt;br /&gt;&lt;searchLink fieldCode=&quot;MM&quot; term=&quot;%22Pyrazoles%22&quot;&gt;Pyrazoles*&lt;/searchLink&gt;/&lt;searchLink fieldCode=&quot;MM&quot; term=&quot;%22Pyrazoles+therapeutic+use%22&quot;&gt;therapeutic use&lt;/searchLink&gt; &lt;br /&gt;&lt;searchLink fieldCode=&quot;MM&quot; term=&quot;%22Pyrazoles%22&quot;&gt;Pyrazoles*&lt;/searchLink&gt;/&lt;searchLink fieldCode=&quot;MM&quot; term=&quot;%22Pyrazoles+administration+%26+dosage%22&quot;&gt;administration &amp; dosage&lt;/searchLink&gt; &lt;br /&gt;&lt;searchLink fieldCode=&quot;MM&quot; term=&quot;%22Benzodioxoles%22&quot;&gt;Benzodioxoles*&lt;/searchLink&gt;/&lt;searchLink fieldCode=&quot;MM&quot; term=&quot;%22Benzodioxoles+therapeutic+use%22&quot;&gt;therapeutic use&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;MH&quot; term=&quot;%22Nutritional+Status%22&quot;&gt;Nutritional Status&lt;/searchLink&gt;/&lt;searchLink fieldCode=&quot;MH&quot; term=&quot;%22Nutritional+Status+drug+effects%22&quot;&gt;drug effects&lt;/searchLink&gt; ; &lt;searchLink fieldCode=&quot;MH&quot; term=&quot;%22Cystic+Fibrosis+Transmembrane+Conductance+Regulator%22&quot;&gt;Cystic Fibrosis Transmembrane Conductance Regulator&lt;/searchLink&gt;/&lt;searchLink fieldCode=&quot;MH&quot; term=&quot;%22Cystic+Fibrosis+Transmembrane+Conductance+Regulator+genetics%22&quot;&gt;genetics&lt;/searchLink&gt; ; &lt;searchLink fieldCode=&quot;MH&quot; term=&quot;%22Lung%22&quot;&gt;Lung&lt;/searchLink&gt;/&lt;searchLink fieldCode=&quot;MH&quot; term=&quot;%22Lung+drug+effects%22&quot;&gt;drug effects&lt;/searchLink&gt; ; &lt;searchLink fieldCode=&quot;MH&quot; term=&quot;%22Lung%22&quot;&gt;Lung&lt;/searchLink&gt;/&lt;searchLink fieldCode=&quot;MH&quot; term=&quot;%22Lung+physiopathology%22&quot;&gt;physiopathology&lt;/searchLink&gt; ; &lt;searchLink fieldCode=&quot;MH&quot; term=&quot;%22Chloride+Channel+Agonists%22&quot;&gt;Chloride Channel Agonists&lt;/searchLink&gt;/&lt;searchLink fieldCode=&quot;MH&quot; term=&quot;%22Chloride+Channel+Agonists+therapeutic+use%22&quot;&gt;therapeutic use&lt;/searchLink&gt; ; &lt;searchLink fieldCode=&quot;MH&quot; term=&quot;%22Chloride+Channel+Agonists%22&quot;&gt;Chloride Channel Agonists&lt;/searchLink&gt;/&lt;searchLink fieldCode=&quot;MH&quot; term=&quot;%22Chloride+Channel+Agonists+administration+%26+dosage%22&quot;&gt;administration &amp; dosage&lt;/searchLink&gt; ; &lt;searchLink fieldCode=&quot;MH&quot; term=&quot;%22Humans%22&quot;&gt;Humans&lt;/searchLink&gt; ; &lt;searchLink fieldCode=&quot;MH&quot; term=&quot;%22Female%22&quot;&gt;Female&lt;/searchLink&gt; ; &lt;searchLink fieldCode=&quot;MH&quot; term=&quot;%22Adult%22&quot;&gt;Adult&lt;/searchLink&gt; ; &lt;searchLink fieldCode=&quot;MH&quot; term=&quot;%22Male%22&quot;&gt;Male&lt;/searchLink&gt; ; &lt;searchLink fieldCode=&quot;MH&quot; term=&quot;%22Retrospective+Studies%22&quot;&gt;Retrospective Studies&lt;/searchLink&gt; ; &lt;searchLink fieldCode=&quot;MH&quot; term=&quot;%22Adolescent%22&quot;&gt;Adolescent&lt;/searchLink&gt; ; &lt;searchLink fieldCode=&quot;MH&quot; term=&quot;%22Young+Adult%22&quot;&gt;Young Adult&lt;/searchLink&gt; ; &lt;searchLink fieldCode=&quot;MH&quot; term=&quot;%22Child%22&quot;&gt;Child&lt;/searchLink&gt; ; &lt;searchLink fieldCode=&quot;MH&quot; term=&quot;%22Treatment+Outcome%22&quot;&gt;Treatment Outcome&lt;/searchLink&gt;
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Aim: Elexacaftor/tezacaftor/ivacaftor (ETI) has markedly improved cystic fibrosis (CF) outcomes. However, its long-term impact on nutrition, metabolism and liver health remains underexplored. We assessed 30-month changes in pulmonary, nutritional, metabolic and inflammatory markers in people with CF (PwCF) homozygous for F508del.&lt;br /&gt;Methods: We retrospectively analysed 112 PwCF (median age-31 years) treated with ETI from July 2021 to December 2024. Clinical, spirometric and biochemical data were collected at baseline and at 6, 12, 24 and 30 months.&lt;br /&gt;Results: ETI produced sustained lung function gains (percent predicted FEV₁ + 15 points at 24 months, p &amp;lt; 0.001), BMI increase (+1.7&#160;kg/m&lt;superscript&gt;2&lt;/superscript&gt; in year-one, p &amp;lt; 0.001) and marked C-reactive protein reduction (-80% at 6&#160;months), with an 85% decrease in pulmonary exacerbations. Nutritional recovery shifted BMI distribution: underweight prevalence declined from 12.5% to 1.8%, while overweight rose from 15.2% to 27.7%. Adolescents improved in weight-for-age Z-scores (+0.42, p = 0.01). Total and LDL cholesterol increased but remained within reference ranges; HDL, triglycerides and glycaemic control stayed stable, with no new cystic fibrosis-related diabetes (CFRD). Vitamin D improved; vitamin B12 fluctuated with supplementation. Mild, transient transaminase elevations occurred in 4.5% of PwCF, with no fibrosis progression (APRI/FIB-4 below risk thresholds).&lt;br /&gt;Conclusion: ETI provides durable multisystem benefits, preserving lung function and improving nutritional and metabolic profiles. However, the shift towards overweight/obesity and biochemical signs of hepatic stress suggests evolving cardiometabolic risks. These findings support early ETI initiation and reinforce the need for ongoing monitoring of nutrition, lipid profile and liver function, together with updated CF care strategies to mitigate long-term cardiometabolic complications.&lt;br /&gt; (&#169; 2026 The Author(s). British Journal of Clinical Pharmacology published by John Wiley &amp; Sons Ltd on behalf of British Pharmacological Society.)
– Name: Ref
  Label: References
  Group: RefInfo
  Data: Snowball JE, Flight WG, Heath L, Koutoukidis DA. A paradigm shift in cystic fibrosis nutritional care: clinicians&#39; views on the management of patients with overweight and obesity. J Cyst Fibros. 2023;22(5):836‐842. doi:10.1016/j.jcf.2023.03.011.&lt;br /&gt;Bell SC, Mall MA, Gutierrez H, et al. The future of cystic fibrosis care: a global perspective. Lancet Respir Med. 2019;7(12):e40. doi:10.1016/S2213‐2600(19)30408‐4.&lt;br /&gt;Bardin E, Pastor A, Semeraro M, et al. Modulators of CFTR. Updates on clinical development and future directions. Eur J Med Chem. 2021;213:113195. doi:10.1016/j.ejmech.2021.113195.&lt;br /&gt;Frantzen T, Barsky S, LaVecchia G, Marowitz M, Wang J. Evolving nutritional needs in cystic fibrosis. Life. 2023;13(7):1431. doi:10.3390/life13071431.&lt;br /&gt;Despotes KA, Ceppe AS, Donaldson SH. Alterations in lipids after initiation of highly effective modulators in people with cystic fibrosis. J Cyst Fibros. 2023;22(6):1024‐1026. doi:10.1016/j.jcf.2023.10.002.&lt;br /&gt;Middleton PG, Mall MA, Dřev&#237;nek P, et al. Elexacaftor‐Tezacaftor‐ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med. 2019;381(19):1809‐1819. doi:10.1056/NEJMoa1908639.&lt;br /&gt;Moran A, Brunzell C, Cohen RC, et al. CFRD guidelines committee. Clinical care guidelines for cystic fibrosis‐related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the pediatric Endocrine Society. Diabetes Care. 2010;33(12):2697‐2708. doi:10.2337/dc10‐1768.&lt;br /&gt;Wilschanski M, Munck A, Carrion E, et al. ESPEN‐ESPGHAN‐ECFS guideline on nutrition care for cystic fibrosis. Clin Nutr. 2024;43(2):413‐445. doi:10.1016/j.clnu.2023.12.017.&lt;br /&gt;Quanjer PH, Stanojevic S, Cole TJ, et al. Multi‐ethnic reference values for spirometry for the 3‐95‐yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40(6):1324‐1343. doi:10.1183/09031936.00080312.&lt;br /&gt;Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518‐526. doi:10.1053/jhep.2003.50346.&lt;br /&gt;Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317‐1325. doi:10.1002/hep.21178.&lt;br /&gt;Sellers Z, Assis D, Paranjape S, et al. Cystic fibrosis screening, evaluation, and management of hepatobiliary disease consensus recommendations. Hepatology. 2024;79(5):1220‐1238. doi:10.1097/HEP.0000000000000646.&lt;br /&gt;Heijerman HGM, McKone EF, Downey DG, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double‐blind, randomised, phase 3 trial. Lancet. 2019;394(10212):1940‐1948. doi:10.1016/S0140‐6736(19)32597‐8.&lt;br /&gt;Vega‐Hernandez G, MacGregor G, Wilfin A, et al. LONGITUDE: an observational study of the long‐term effectiveness of elexacaftor/tezacaftor/ivacaftor in people aged ≥12 years with cystic fibrosis using data from the United Kingdom cystic fibrosis registry ‐ 2‐year analysis. J Cyst Fibros. 24(4):716‐723. doi:10.1016/j.jcf.2025.04.012.&lt;br /&gt;Perrotta N, Fiorito LA, Gentile R, et al. Real‐world evaluation of outcomes and safety of Elexacaftor/Tezacaftor/ivacaftor in pediatric patients with cystic fibrosis: a retrospective study. Clin Transl Sci. 2025;18(10):e70373. doi:10.1111/cts.70373.&lt;br /&gt;Keens T, Hoffman V, Topuria I, et al. VX19‐CFD‐003 study group. Real‐world effectiveness of elexacaftor/tezacaftor/ivacaftor on the burden of illness in adolescents and adults with cystic fibrosis. Heliyon. 2024;10(7):e28508. doi:10.1016/j.heliyon.2024.e28508.&lt;br /&gt;Perrotta N, Fiorito LA, Casini G, et al. Improved clinical outcomes with Elexacaftor/Tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease: real‐world evidence from an Italian single‐center study. Pharmacol Res Perspect. 2025;13(2):e70083. doi:10.1002/prp2.70083.&lt;br /&gt;L&#243;pez C&#225;rdenes CM, Merino S&#225;nchez‐Ca&#241;ete A, Vicente Santamar&#237;a S, et al. Effects on growth, weight and body composition after CFTR modulators in children with cystic fibrosis. Pediatr Pulmonol. 2024;59(12):3632‐3640. doi:10.1002/ppul.27272.&lt;br /&gt;Sandersa DB, Zhangb Z, Farrellc P, Lai HCJ. Early life growth patterns persist for 12 years and impact pulmonary outcomes in cystic fibrosis. J Cyst Fibros. 2018;17(4):528‐535. doi:10.1016/j.jcf.2018.01.006.&lt;br /&gt;Westh&#246;lter D, Haubold J, Welsner M, et al. Elexacaftor/tezacaftor/ivacaftor influences body composition in adults with cystic fibrosis: a fully automated CT‐based analysis. Sci Rep. 2024;14(1):9465. doi:10.1038/s41598‐024‐59622‐2.&lt;br /&gt;Castaldo A, Cimbalo C, Fevola C, et al. The treatment with Elexacaftor/Tezacaftor/ivacaftor significantly increases serum bilirubin and decreases blood platelets in children and adolescents with cystic fibrosis homozygous or double heterozygous for the F508del CFTR variant. J Cyst Fibros. 24(6):1149‐1155.&lt;br /&gt;Pepe A, Fevola C, Dolce D, et al. Elexacaftor/tezacaftor/ivacaftor and inflammation in children and adolescents with cystic fibrosis: a retrospective dual‐center cohort study. Ther Adv Respir Dis. 2025;19. doi:10.1177/17534666251314706.&lt;br /&gt;Bailey J, Krick S, Fontaine KR. The changing landscape of nutrition in cystic fibrosis: the emergence of overweight and obesity. Nutrients. 2022;14(6):1216. doi:10.3390/nu14061216.&lt;br /&gt;Castaldo A, Iacotucci P, Bagnasco S, et al. Liver biochemical indexes and cholesterol metabolism in cystic fibrosis patients with F508del/CFTR variant genotype after elexacaftor/tezacaftor/ivacaftor treatment. Sci Rep. 2024;14(1):17422. doi:10.1038/s41598‐024‐68511‐7.&lt;br /&gt;Vavrina K, Griffin TB, Jones AM, Schindler T, Bui TN, Sankararaman S. Evolving nutrition therapy in cystic fibrosis: adapting to the CFTR modulator era. Nutr Clin Pract. 2025;40(4):816‐828. doi:10.1002/ncp.11332.&lt;br /&gt;Ratti GA, Smith H, Mirfakhraee S, et al. Development of metabolic syndrome in people with cystic fibrosis one year after exposure to elexacaftor‐tezacaftor‐ivacaftor. J Cyst Fibros. 2025;24(1):47‐52. doi:10.1016/j.jcf.2024.09.022.&lt;br /&gt;Castaldo A, Gelzo M, Iacotucci P, et al. One year of treatment with elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis homozygous for the F508del mutation causes a significant increase in liver biochemical indexes. Front. Mol. Biosci., 08 January 2024. Sec Cell Biochem. 2023;10.&lt;br /&gt;Clayton LJ, Shepherd AI, Corbett J, et al. Cardiovascular function in people with cystic fibrosis on Elexacaftor/Tezacaftor/ivacaftor: a cross‐sectional, observational, single‐Centre study. J Cyst Fibros. 2025;S1569‐1993(25):00052‐00059. doi:10.1016/j.jcf.2025.02.001.&lt;br /&gt;Betapudi B, Aleem A, Kothadia JP. Cystic Fibrosis and Liver Disease. 2023 Jan 9. In: StatPearls. StatPearls Publishing; 2025. PMID: 32310546.&lt;br /&gt;Liang X, Hou X, Bouhamdan M, et al. Sotagliflozin attenuates liver‐associated disorders in cystic fibrosis rabbits. JCI Insight. 2024;9(6):e165826. doi:10.1172/jci.insight.165826.&lt;br /&gt;Ticona JH, Lapinel N, Wang J. Future comorbidities in an aging cystic fibrosis population. Life (Basel). 2023;13(6):1305. doi:10.3390/life13061305.&lt;br /&gt;Blankenship S, Landis AR, Harrison Williams E, et al. What the future holds: cystic fibrosis and aging. Front Med (Lausanne). 2024;10:1340388. doi:10.3389/fmed.2023.1340388.&lt;br /&gt;Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cystic fibrosis‐related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care. 2009;32(9):1626‐1631. doi:10.2337/dc09‐0586.&lt;br /&gt;Merjaneh L, Hasan S, Kasim N, Ode KL. The role of modulators in cystic fibrosis related diabetes. J Clin Transl Endocrinol. 2021;27:100286. doi:10.1016/j.jcte.2021.100286.&lt;br /&gt;Lurquin F, Gohy S. Hermans MP et al combined CFTR modulator therapies are linked with anabolic benefits and insulin‐sparing in cystic fibrosis‐related diabetes. J Clin Transl Endocrinol. 2023;33:100320. doi:10.1016/j.jcte.2023.100320.&lt;br /&gt;Lurquin F, Buysschaert M, Preumont V. Advances in cystic fibrosis‐related diabetes: current status and future directions. Diabetes Metab Syndr. 2023;17(11):102899. doi:10.1016/j.dsx.2023.102899.&lt;br /&gt;Sankararaman S, Hendrix SJ, Schindler T. Update on the management of vitamins and minerals in cystic fibrosis. Nutr Clin Pract. 2022;37(5):1074‐1087. doi:10.1002/ncp.10899.&lt;br /&gt;Hergenroeder GE, Faino A, Bridges G, et al. The impact of elexacaftor/tezacaftor/ivacaftor on fat‐soluble vitamin levels in people with cystic fibrosis. J Cyst Fibros. 2023;22(6):1048‐1053. doi:10.1016/j.jcf.2023.08.002.&lt;br /&gt;Crehu&#225;‐Gaudiza E, Vicente Santamar&#237;a S, &#193;lvarez Beltr&#225;n M, et al. Effect of cystic fibrosis modulator therapies on serum levels of fat‐soluble vitamins. JPGN Rep. 2025;6(2):146‐152. doi:10.1002/jpr3.70007.&lt;br /&gt;Jarosz‐Griffiths HH, Caley LR, Lara‐Reyna S, et al. Heightened mitochondrial respiration in CF cells is normalised by triple CFTR modulator therapy through mechanisms involving calcium. Heliyon. 2024;10(20):e39244. doi:10.1016/j.heliyon.2024.e39244.&lt;br /&gt;Zhang S, Shrestha CL, Robledo‐Avila F, et al. Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor. Eur Respir J. 2023;61(4):2102861. doi:10.1183/13993003.02861‐2021.&lt;br /&gt;Tewkesbury DH, Athwal V, Bright‐Thomas RJ, Jones AM, Barry PJ. Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on liver tests at a large single adult cystic fibrosis Centre. J Cyst Fibros. 2023;22(2):256‐262. doi:10.1016/j.jcf.2023.01.007.
– Name: SubjectMinor
  Label: Contributed Indexing
  Group:
  Data: &lt;i&gt;Keywords: &lt;/i&gt;Elexacaftor/Tezacaftor/ivacaftor; cystic fibrosis; inflammation; liver function; metabolic health; nutritional status
– Name: NumberCAS
  Label: Substance Nomenclature
  Group: ID
  Data: 0 (Quinolones)&lt;br /&gt;0 (Indoles)&lt;br /&gt;0 (Pyrrolidines)&lt;br /&gt;0 (Aminophenols)&lt;br /&gt;RRN67GMB0V (elexacaftor)&lt;br /&gt;8RW88Y506K (tezacaftor)&lt;br /&gt;0 (Pyridines)&lt;br /&gt;126880-72-6 (Cystic Fibrosis Transmembrane Conductance Regulator)&lt;br /&gt;0 (Pyrazoles)&lt;br /&gt;0 (Benzodioxoles)&lt;br /&gt;0 (Chloride Channel Agonists)
– Name: DateEntry
  Label: Entry Date(s)
  Group: Date
  Data: &lt;i&gt;Date Created: &lt;/i&gt;20260124 &lt;i&gt;Date Completed: &lt;/i&gt;20260630 &lt;i&gt;Latest Revision: &lt;/i&gt;20260630
– Name: DateUpdate
  Label: Update Code
  Group: Date
  Data: 20260701
– Name: PubmedCentralID
  Label: PubMed Central ID
  Group: ID
  Data: PMC13206182
– Name: DOI
  Label: DOI
  Group: ID
  Data: 10.1002/bcp.70460
– Name: AN
  Label: PMID
  Group: ID
  Data: 41578635
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=cmedm&AN=41578635
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1002/bcp.70460
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1822
    Subjects:
      – SubjectFull: Nutritional Status drug effects
        Type: general
      – SubjectFull: Cystic Fibrosis Transmembrane Conductance Regulator genetics
        Type: general
      – SubjectFull: Lung drug effects
        Type: general
      – SubjectFull: Lung physiopathology
        Type: general
      – SubjectFull: Chloride Channel Agonists therapeutic use
        Type: general
      – SubjectFull: Chloride Channel Agonists administration & dosage
        Type: general
      – SubjectFull: Humans
        Type: general
      – SubjectFull: Female
        Type: general
      – SubjectFull: Adult
        Type: general
      – SubjectFull: Male
        Type: general
      – SubjectFull: Retrospective Studies
        Type: general
      – SubjectFull: Adolescent
        Type: general
      – SubjectFull: Young Adult
        Type: general
      – SubjectFull: Child
        Type: general
      – SubjectFull: Treatment Outcome
        Type: general
      – SubjectFull: Cystic Fibrosis drug therapy
        Type: general
      – SubjectFull: Cystic Fibrosis physiopathology
        Type: general
      – SubjectFull: Cystic Fibrosis genetics
        Type: general
      – SubjectFull: Cystic Fibrosis metabolism
        Type: general
      – SubjectFull: Quinolones therapeutic use
        Type: general
      – SubjectFull: Quinolones administration & dosage
        Type: general
      – SubjectFull: Indoles therapeutic use
        Type: general
      – SubjectFull: Indoles administration & dosage
        Type: general
      – SubjectFull: Pyrrolidines therapeutic use
        Type: general
      – SubjectFull: Pyrrolidines administration & dosage
        Type: general
      – SubjectFull: Aminophenols therapeutic use
        Type: general
      – SubjectFull: Aminophenols administration & dosage
        Type: general
      – SubjectFull: Aminophenols pharmacology
        Type: general
      – SubjectFull: Pyridines therapeutic use
        Type: general
      – SubjectFull: Pyridines administration & dosage
        Type: general
      – SubjectFull: Pyrazoles therapeutic use
        Type: general
      – SubjectFull: Pyrazoles administration & dosage
        Type: general
      – SubjectFull: Benzodioxoles therapeutic use
        Type: general
    Titles:
      – TitleFull: Long-term impact of Elexacaftor/Tezacaftor/ivacaftor on pulmonary, nutritional and metabolic outcomes in homozygous F508del cystic fibrosis patients: A real-world cohort study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Perrotta N
      – PersonEntity:
          Name:
            NameFull: Fiorito LA
      – PersonEntity:
          Name:
            NameFull: Vescovo R
      – PersonEntity:
          Name:
            NameFull: Virgilio A
      – PersonEntity:
          Name:
            NameFull: Amato G
      – PersonEntity:
          Name:
            NameFull: Cimino G
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 06
              Text: 2026 Jun
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1365-2125
          Numbering:
            – Type: volume
              Value: 92
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: British journal of clinical pharmacology
              Type: main
ResultId 1